Skip to main content
. 2017 Jul 20;8(65):108522–108533. doi: 10.18632/oncotarget.19411

Figure 6. ABT-737 down-regulates BIM E3/E4 ratio and efficiently induces EGFR-mutant NSCLC cells apoptosis when combined with erlotinib.

Figure 6

(A) PC-3 and HCC2279 cells were treated with erlotinib (2 μM) and/or ABT-737 (5 μM) for 12 hours. The mRNA expression of BIM was assayed by RT-PCR. (B) PC-3 and HCC2279 cells were treated with erlotinib (2 μM) and/or ABT-737 (5 μM) for 12 hours. The ratio of exon 3 to exon 4-containing transcripts treated with each compound were assessed (p < 0.05). (C, D). The cells apoptotic ratio was determined by DNA fragmentation(C) and Annexin V/PI (D). (E) HCC827 and HCC2279 cells were treated with erlotinib (2 μM) and/or ABT-737 (5 μM) for 48 hours. Collecting these cells and detecting the indicated proteins by immunoblotting assay.